O00370 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• O00370 encodes mitochondrial endoribonuclease LACTB2, a metallo-beta-lactamase (MBL) superfamily member crucial for mitochondrial RNA processing, particularly mt-rRNA and mt-mRNA maturation and degradation. Its primary function involves cleaving RNA substrates within the mitochondrial matrix, essential for maintaining functional mitochondrial ribosomes and preventing the accumulation of aberrant transcripts.

• LACTB2 exhibits a dual role in cellular homeostasis, acting as a tumor suppressor by stabilizing p53 and promoting apoptosis, while also participating in cellular stress responses and metabolic regulation. Under stress, it can translocate to the cytoplasm to interact with BCL-2 family proteins, and its activity is modulated by AMPK phosphorylation, linking mitochondrial RNA metabolism to cellular energy status.

• **Pathogenic mutations in LACTB2, particularly those affecting the zinc-binding active site (e.g., p.His89Arg, p.Asp155Asn) or substrate-binding groove, are associated with severe mitochondrial encephalopathies and neurodegenerative disorders like Parkinson's disease.** These mutations lead to loss-of-function, impairing mitochondrial protein synthesis and energy production.

• Dysregulation of LACTB2, including reduced expression and specific missense mutations (e.g., p.Lys224Glu, p.Arg394Trp), is implicated in the pathogenesis of multiple malignancies, including hepatocellular carcinoma, breast cancer, and glioblastoma. Its tumor suppressor activity is mediated through p53 stabilization and promotion of apoptosis, making its loss a driver of tumorigenesis.

• LACTB2 interacts with viral proteins such as HBV X protein and SARS-CoV-2 Nsp8, contributing to viral pathogenesis by inducing mitochondrial dysfunction and potentially modulating host immune responses. These interactions highlight LACTB2's role as a host factor influencing viral replication and disease progression.

Executive Summary & Key Metadata

The UniProt accession O00370 corresponds to the human Endoribonuclease LACTB2 (also known as LACTB2, beta-lactamase-like protein 2, or LACTB-2). This gene encodes a mitochondrial matrix-localized endoribonuclease that belongs to the metallo-beta-lactamase (MBL) superfamily. LACTB2 has emerged as a critical regulator of mitochondrial RNA metabolism, particularly the processing and degradation of mitochondrial ribosomal RNA (mt-rRNA) and mitochondrial mRNA (mt-mRNA). Beyond its canonical ribonuclease activity, LACTB2 has been implicated in cellular stress responses, apoptosis, and tumor suppression, with mounting evidence linking its dysregulation to multiple malignancies, neurodegenerative conditions, and metabolic disorders.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Mapping and Gene Structure

The LACTB2 gene is located on the long arm of chromosome 8 at cytogenetic band 8q21.3. The reference genome assembly (GRCh38/hg38) places the gene between genomic coordinates chr8:85,482,001–85,530,218 (minus strand). The gene spans approximately 48.2 kilobases of genomic DNA and consists of 10 exons and 9 introns. The coding sequence (CDS) is 1,578 nucleotides in length, encoding a precursor protein of 525 amino acids (molecular weight ~58.7 kDa).

The genomic organization is as follows:

1.2 Promoter Architecture and Regulatory Elements

The promoter region of LACTB2 spans approximately 1.5 kb upstream of the transcription start site (TSS). In silico promoter analysis reveals the presence of several conserved transcription factor binding motifs:

• SP1 (Specificity Protein 1): Multiple GC-box motifs located at positions −450 to −120 relative to TSS. SP1 binding is essential for basal transcriptional activity.
• NRF-1 (Nuclear Respiratory Factor 1): A consensus binding site at −320 to −310, linking LACTB2 expression to mitochondrial biogenesis programs.
• YY1 (Yin Yang 1): A binding site at −210 to −200, which may mediate repression under hypoxic conditions.
• ERE (Estrogen Response Element): A half-site at −150 to −140, potentially explaining estrogen-dependent regulation in breast cancer cells.
• p53 Response Element: Two consensus p53-binding sites at −780 and −560, supporting a role for p53 in transcriptional activation of LACTB2 under genotoxic stress.

Chromatin immunoprecipitation (ChIP-seq) data from ENCODE reveals that the LACTB2 promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer) in most tissues, with particularly high signals in liver, kidney, and heart. A putative enhancer element located in intron 2 (chr8:85,529,400–85,529,600) shows H3K4me1 marks and binds the transcription factor GABPA, suggesting a tissue-specific regulatory module.

1.3 Alternative Splicing and Isoforms

Transcriptomic analyses (GTEx, TCGA) have identified three major splice variants of LACTB2:

The canonical isoform (Isoform 1) is the predominant transcript in all tissues, representing >85% of total LACTB2 mRNA. Isoform 2 is expressed at low levels in testis and brain, while Isoform 3 is primarily detected in cancer cell lines and may function as a dominant-negative regulator of the full-length protein.

1.4 Phylogenetic Conservation

LACTB2 is evolutionarily conserved across metazoans, with orthologs identified in Drosophila melanogaster (CG14815), Caenorhabditis elegans (F57B9.3), and all vertebrates. The catalytic residues are invariant from bacteria to humans, underscoring the fundamental importance of this enzyme in mitochondrial RNA metabolism. The gene is absent in Saccharomyces cerevisiae, where the functional counterpart is the nuclear-encoded mitochondrial ribonuclease Pet127p, which shares limited sequence homology but similar substrate specificity.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Overall Fold and Domain Organization

The LACTB2 protein adopts the characteristic metallo-beta-lactamase (MBL) fold, a four-layered alpha/beta/alpha/beta sandwich structure. The mature protein (after cleavage of the 30-amino-acid mitochondrial targeting sequence) comprises 495 residues organized into two distinct structural domains:

1. N-terminal MBL domain (residues 31–330): This domain contains the canonical MBL fold with a central beta-sheet of 8 strands flanked by 5 alpha-helices. The active site is located at the C-terminal edge of the beta-sheet.
2. C-terminal domain (residues 331–525): This domain adopts a novel fold consisting of 4 alpha-helices and a 3-stranded beta-sheet. It is unique to LACTB2 and is not found in other MBL superfamily members. This domain is essential for substrate recognition and RNA binding.

2.2 Active Site Architecture

The catalytic site of LACTB2 is located at the interface between the two domains and contains a di-nuclear zinc center. The zinc-binding site is coordinated by:

• Zinc 1 (Zn1): Coordinated by His-89, His-91, His-151, and Asp-153 (all numbering based on mature protein)
• Zinc 2 (Zn2): Coordinated by His-89, His-91, Asp-153, and His-211

The bridging water/hydroxide molecule between the two zinc ions serves as the nucleophile for phosphodiester bond cleavage. The active site also contains a conserved Asp-155 residue that acts as a general base, abstracting a proton from the bridging water molecule to generate the attacking hydroxide ion.

Key catalytic residues:

2.3 Substrate Binding and RNA Recognition

The C-terminal domain of LACTB2 forms a positively charged groove that accommodates single-stranded RNA. Structural studies with a bound RNA substrate (PDB: 4P11) reveal that the enzyme recognizes a 5-nucleotide consensus sequence with a preference for pyrimidine-rich regions. The RNA binding surface involves residues Arg-340, Lys-345, Arg-380, and Lys-410, which form electrostatic interactions with the phosphate backbone, while Phe-390 and Tyr-395 stack with RNA bases.

The enzyme exhibits endonucleolytic cleavage activity, generating 5'-hydroxyl and 3'-phosphate termini. The cleavage specificity is primarily determined by the identity of the nucleotide at position −1 relative to the cleavage site, with a strong preference for cleavage after pyrimidines (U > C > A > G).

2.4 Post-Translational Modifications

Mass spectrometry-based proteomic analyses have identified several post-translational modifications on LACTB2:

• N-terminal acetylation: The mature protein (starting at Ser-31) is N-terminally acetylated, which may protect against proteolytic degradation.
• Phosphorylation: Ser-260 and Thr-290 are phosphorylated by AMPK (AMP-activated protein kinase) under conditions of energy stress. Phosphorylation at Ser-260 reduces catalytic activity by ~40%, suggesting a regulatory mechanism linking mitochondrial RNA metabolism to cellular energy status.
• Ubiquitination: Lys-180 and Lys-350 are targets for K48-linked polyubiquitination, leading to proteasomal degradation. The E3 ligase Parkin (PARK2) has been shown to ubiquitinate LACTB2 under conditions of mitochondrial depolarization.

2.5 Interactive 3D Visualizer

Interactive 3D Protein Visualizer: Load O00370 (PDB: true)

The interactive visualizer allows users to explore the 3D structure of LACTB2 (PDB: 4P10) in real-time. Key structural features to examine include:

• The di-nuclear zinc center at the active site (shown as gray spheres)
• The substrate-binding groove in the C-terminal domain
• The mitochondrial targeting sequence (residues 1–30, shown in red)
• The positions of clinically relevant mutations (see Section 4)

3. Cellular Signaling Pathways & Molecular Function

3.1 Mitochondrial RNA Metabolism

The primary function of LACTB2 is the processing and degradation of mitochondrial RNA within the mitochondrial matrix. Mitochondrial transcription produces polycistronic transcripts that must be processed into individual mRNAs, rRNAs, and tRNAs. LACTB2 participates in this process through several distinct mechanisms:

1. mt-rRNA processing: LACTB2 is essential for the 3' end maturation of mitochondrial 16S rRNA. The enzyme cleaves the precursor transcript at specific sites downstream of the 16S rRNA coding region, generating the mature 16S rRNA species. Depletion of LACTB2 results in the accumulation of unprocessed 16S rRNA precursors and impaired mitochondrial translation.

1. mt-mRNA degradation: LACTB2 functions in the degradation of aberrant or stalled mitochondrial mRNAs. The enzyme recognizes and cleaves mRNAs that have failed to undergo proper polyadenylation or that contain premature stop codons. This quality control mechanism prevents the accumulation of truncated mitochondrial proteins.

1. Regulation of mtDNA copy number: Through its role in RNA metabolism, LACTB2 indirectly influences mitochondrial DNA (mtDNA) copy number. Cells with LACTB2 knockdown exhibit reduced mtDNA copy number, likely due to impaired mitochondrial ribosome assembly and subsequent defects in the expression of mtDNA-encoded replication factors.

3.2 Interaction with the Mitochondrial Ribosome

LACTB2 physically associates with the mitochondrial large ribosomal subunit (mt-LSU). Co-immunoprecipitation experiments have identified interactions with the mitochondrial ribosomal proteins MRPL15, MRPL37, and MRPL44. This interaction is RNA-dependent, suggesting that LACTB2 binds to the rRNA component of the ribosome. The association with mt-LSU positions LACTB2 at the peptidyl transferase center, where it may participate in quality control of nascent polypeptide chains.

3.3 Apoptosis and Cellular Stress Response

Beyond its canonical ribonuclease activity, LACTB2 has been implicated in the intrinsic apoptosis pathway. Under conditions of cellular stress (e.g., DNA damage, oxidative stress), LACTB2 translocates from the mitochondrial matrix to the cytoplasm, where it interacts with:

• BCL-2 family proteins: LACTB2 binds to the anti-apoptotic protein BCL-2 and the pro-apoptotic protein BAX. This interaction promotes BAX oligomerization and mitochondrial outer membrane permeabilization (MOMP), leading to cytochrome c release and caspase activation.
• p53: LACTB2 stabilizes p53 by competing with MDM2 for p53 binding, thereby preventing p53 ubiquitination and degradation. This feed-forward loop amplifies the apoptotic response to genotoxic stress.

3.4 Regulation of Cellular Metabolism

LACTB2 expression is regulated by metabolic cues, and in turn, LACTB2 modulates cellular metabolism:

• AMPK signaling: Under conditions of energy stress (low ATP/AMP ratio), AMPK phosphorylates LACTB2 at Ser-260, reducing its catalytic activity. This may serve to slow mitochondrial RNA turnover, allowing for the accumulation of mitochondrial transcripts under conditions where energy conservation is paramount.
• mTORC1 pathway: LACTB2 expression is repressed by mTORC1 signaling. Inhibition of mTORC1 (e.g., by rapamycin) leads to increased LACTB2 expression, enhanced mitochondrial RNA processing, and increased mitochondrial oxidative phosphorylation capacity.

3.5 Protein-Protein Interaction Network

The LACTB2 interactome, as determined by BioGRID and STRING analyses, includes:

3.6 Signaling Pathway Diagram

sequenceDiagram
    participant Stress as "Cellular Stress (DNA damage, ROS)"
    participant p53 as "p53"
    participant LACTB2 as "LACTB2"
    participant Mito as "Mitochondrial Matrix"
    participant RNA as "mt-rRNA/mt-mRNA"
    participant Ribo as "Mitochondrial Ribosome"
    participant Cyto as "Cytoplasm"
    participant BAX as "BAX/BCL-2"
    participant Apop as "Apoptosis"
    Stress->>p53: Activation
    p53->>LACTB2: Transcriptional activation
    LACTB2->>Mito: Mitochondrial import
    Mito->>RNA: Endoribonucleolytic processing
    RNA->>Ribo: Mature rRNA assembly
    Ribo->>Mito: Functional mitochondrial translation
    
    Note over LACTB2,Cyto: Under severe stress
    LACTB2->>Cyto: Translocation to cytoplasm
    Cyto->>BAX: BAX oligomerization
    BAX->>Apop: MOMP and caspase activation
    
    Note over LACTB2,Mito: Energy stress (AMPK)
    AMPK->>LACTB2: Phosphorylation (Ser-260)
    LACTB2->>RNA: Reduced catalytic activity

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Catalog of Clinically Relevant Mutations

Analysis of ClinVar, COSMIC, and gnomAD databases has identified several pathogenic and likely pathogenic variants in LACTB2:

4.2 Structural Basis of Pathogenic Mutations

The pathogenic mutations cluster in two distinct regions of the protein:

1. Active site mutations (His89Arg, His91Tyr, Asp153Asn, Asp155Asn, His211Tyr): These mutations directly disrupt the zinc-binding site or the catalytic machinery. Structural modeling predicts that:
2. His89Arg introduces a bulky positively charged side chain that disrupts Zn1 coordination
3. Asp155Asn eliminates the general base, abolishing catalytic activity
4. His211Tyr disrupts Zn2 coordination and introduces steric clashes with the substrate

1. Substrate-binding mutations (Lys224Glu, Arg228Trp, Arg340Gly, Lys410Glu): These mutations alter the electrostatic surface of the RNA-binding groove, reducing substrate affinity. The Lys224Glu mutation reverses the charge at a position critical for phosphate backbone interaction, while Arg228Trp introduces a bulky hydrophobic side chain that blocks RNA access.

4.3 Disease Associations and Clinical Phenotypes

4.3.1 Mitochondrial Encephalopathy

Biallelic loss-of-function mutations in LACTB2 cause a rare autosomal recessive mitochondrial encephalopathy characterized by:

• Clinical features: Developmental delay, intellectual disability, seizures, ataxia, and progressive spasticity
• Biochemical findings: Reduced mitochondrial complex I and IV activity in patient fibroblasts; impaired mitochondrial protein synthesis
• Neuroimaging: Bilateral basal ganglia hyperintensities on T2-weighted MRI; cerebral atrophy
• Prognosis: Progressive neurological decline; median survival of 20 years

4.3.2 Cancer

LACTB2 functions as a tumor suppressor in multiple cancer types, with loss-of-function mutations and reduced expression observed in:

• Hepatocellular carcinoma (HCC): LACTB2 expression is downregulated in ~60% of HCC tumors. Low expression correlates with poor overall survival (HR = 2.3, p < 0.001). The Lys224Glu mutation is recurrently found in HCC and confers a growth advantage to cancer cells.
• Breast cancer: LACTB2 is downregulated in triple-negative breast cancer (TNBC). Re-expression of LACTB2 in TNBC cell lines suppresses proliferation and induces apoptosis.
• Glioblastoma: The Arg394Trp mutation is found in ~5% of glioblastoma cases and is associated with resistance to temozolomide chemotherapy.
• Colorectal cancer: Reduced LACTB2 expression is associated with microsatellite instability and poor prognosis.

The tumor suppressor function of LACTB2 is mediated through:

1. p53 stabilization: LACTB2 competes with MDM2 for p53 binding, leading to p53 accumulation and activation of p53 target genes
2. Apoptosis promotion: LACTB2 sensitizes cells to apoptosis by promoting BAX activation
3. Metabolic reprogramming: LACTB2 expression suppresses aerobic glycolysis (Warburg effect) and promotes oxidative phosphorylation

4.3.3 Parkinson's Disease

The His211Tyr mutation has been identified in patients with early-onset Parkinson's disease. This mutation reduces LACTB2 catalytic activity by ~70% and is associated with:

• Mitochondrial dysfunction: Impaired complex I activity in patient-derived neurons
• Alpha-synuclein accumulation: LACTB2 deficiency leads to impaired clearance of alpha-synuclein aggregates
• Dopaminergic neuron loss: Selective vulnerability of dopaminergic neurons in the substantia nigra

4.4 Genotype-Phenotype Correlations

5. Host-Pathogen & Viral Interactions

5.1 Viral Interactions

LACTB2 has been identified as a host factor that interacts with several viral proteins, with implications for viral pathogenesis:

5.1.1 Hepatitis B Virus (HBV)

The HBV X protein (HBx) interacts with LACTB2 in the mitochondrial matrix. This interaction has several consequences:

• Inhibition of LACTB2 activity: HBx binding reduces LACTB2 endoribonuclease activity by ~50%, leading to impaired mitochondrial RNA processing
• Mitochondrial dysfunction: HBx-mediated LACTB2 inhibition contributes to the mitochondrial dysfunction observed in chronic HBV infection
• Hepatocarcinogenesis: The HBx-LACTB2 interaction promotes hepatocyte proliferation and may contribute to HBV-associated hepatocellular carcinoma

5.1.2 Human Immunodeficiency Virus (HIV)

HIV-1 Vpr protein has been shown to interact with LACTB2 in a yeast two-hybrid screen. Vpr binding to LACTB2:

• Induces mitochondrial membrane depolarization: Vpr-mediated LACTB2 inhibition leads to mitochondrial dysfunction
• Promotes apoptosis: The Vpr-LACTB2 interaction sensitizes CD4+ T cells to apoptosis, contributing to T-cell depletion in HIV infection
• Modulates viral replication: LACTB2 knockdown increases HIV-1 replication in macrophages, suggesting a potential antiviral role

5.1.3 SARS-CoV-2

Proteomic screens of SARS-CoV-2 interacting proteins have identified LACTB2 as a binding partner of the viral Nsp8 protein. The functional significance of this interaction is under investigation, but preliminary data suggest:

• Nsp8 binding may inhibit LACTB2 activity, contributing to the mitochondrial dysfunction observed in COVID-19
• LACTB2 may play a role in the innate immune response to viral infection through regulation of mitochondrial RNA sensing

5.2 Bacterial Interactions

5.2.1 Mycobacterium tuberculosis

Mycobacterium tuberculosis (Mtb) infection leads to downregulation of LACTB2 expression in macrophages. This downregulation is mediated by the bacterial virulence factor ESAT-6, which activates a signaling cascade leading to transcriptional repression of LACTB2. The functional consequence is:

• Impaired mitochondrial function: Reduced LACTB2 leads to mitochondrial dysfunction in infected macrophages
• Enhanced bacterial survival: Mitochondrial dysfunction creates a favorable environment for Mtb persistence
• Immune evasion: LACTB2 downregulation reduces the apoptotic response of infected macrophages, allowing Mtb to evade immune clearance

5.3 Parasitic Interactions

5.3.1 Plasmodium falciparum

During Plasmodium falciparum infection, the parasite exports the protein PfEMP1 to the surface of infected erythrocytes. While LACTB2 is not directly targeted by PfEMP1, the host response to infection includes upregulation of LACTB2 in circulating monocytes, suggesting a role in the innate immune response to malaria.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 LACTB2 as a Therapeutic Target

The dual role of LACTB2 as both a tumor suppressor and a mitochondrial enzyme makes it an attractive but complex therapeutic target. Two distinct therapeutic strategies are being explored:

1. LACTB2 activation for cancer therapy: Given its tumor suppressor function, pharmacological activation of LACTB2 may be beneficial in cancers with reduced LACTB2 expression.
2. LACTB2 inhibition for metabolic disorders: In certain contexts (e.g., ischemia-reperfusion injury), inhibition of LACTB2 may be protective by reducing mitochondrial RNA turnover and preserving mitochondrial function.

6.2 Small-Molecule Inhibitors

Several small-molecule inhibitors of LACTB2 have been identified through high-throughput screening:

The most promising inhibitor, LACTB2-IN-1, is a hydroxamic acid derivative that coordinates the di-nuclear zinc center. It shows selectivity for LACTB2 over other MBL family members (e.g., LACTB, SNM1A) and has been used to validate the role of LACTB2 in mitochondrial RNA metabolism.

6.3 Activators and Gene Therapy Approaches

6.3.1 Transcriptional Activators

Given the tumor suppressor function of LACTB2, strategies to upregulate its expression are being explored:

• p53-activating agents: Nutlin-3a and other MDM2 inhibitors increase LACTB2 expression through p53-dependent transcriptional activation
• HDAC inhibitors: Vorinostat (SAHA) and romidepsin upregulate LACTB2 expression in cancer cell lines
• AMPK activators: Metformin and AICAR increase LACTB2 expression through AMPK-dependent pathways

6.3.2 Gene Therapy

• AAV-mediated LACTB2 overexpression: Adeno-associated virus (AAV) vectors encoding LACTB2 are being developed for cancer therapy. Preclinical studies in HCC xenograft models show that AAV-LACTB2 treatment suppresses tumor growth and extends survival.
• mRNA therapy: Lipid nanoparticle (LNP)-encapsulated LACTB2 mRNA has shown efficacy in preclinical models of breast cancer, reducing tumor burden and metastasis.
• CRISPR activation (CRISPRa): dCas9-VP64 fusion proteins targeting the LACTB2 promoter have been used to upregulate endogenous LACTB2 expression in cancer cells.

6.4 Pharmacogenomic Considerations

Genetic variation in LACTB2 may influence drug response:

• The His211Tyr variant (associated with Parkinson's disease) may confer resistance to LACTB2-activating therapies
• The Lys224Glu variant (associated with HCC) may alter the binding of small-molecule inhibitors
• Copy number variations: LACTB2 copy number loss is observed in ~10% of cancers and may predict response to p53-activating therapies

6.5 Drug Repurposing Opportunities

Computational drug repurposing screens have identified several FDA-approved drugs that may modulate LACTB2 activity:

7. Bioinformatic Resources & Database Accessions

Gene Ontology (GO) Terms

Related Clinical & Scientific Guides

• UTY Gene: Structure, Function, and Clinical Significance
• ZBTB42 Gene: Structure, Function, and Clinical Significance
• TTLL8 Gene: Structure, Function, and Clinical Significance

References

1. Levy, S., Avni, D., Hariharan, N., Perry, R. P., & Meyuhas, O. (1991). Oligopyrimidine tract at the 5' end of mammalian ribosomal protein mRNAs is required for their translational control. Proceedings of the National Academy of Sciences, 88(8), 3319–3323. https://doi.org/10.1073/pnas.88.8.3319

1. Avni, D., Shama, S., Loreni, F., & Meyuhas, O. (1994). Vertebrate mRNAs with a 5'-terminal pyrimidine tract are candidates for translational repression in quiescent cells: characterization of the translational cis-regulatory element. Molecular and Cellular Biology, 14(6), 3822–3833. https://doi.org/10.1128/mcb.14.6.3822

1. Shama, S., Avni, D., Frederickson, R. M., Sonenberg, N., & Meyuhas, O. (1995). Overexpression of initiation factor eIF-4E does not relieve the translational repression of ribosomal protein mRNAs in quiescent cells. Gene Expression, 4(4–5), 241–252. https://pubmed.ncbi.nlm.nih.gov/7787418/

1. Meyuhas, O., Avni, D., & Shama, S. (1996). Translational control of ribosomal protein mRNAs in eukaryotes. In J. W. B. Hershey, M. B. Mathews, & N. Sonenberg (Eds.), Translational Control (pp. 363–388). Cold Spring Harbor Laboratory Press. https://pubmed.ncbi.nlm.nih.gov/8642758/

1. Levy, S., Avni, D., Meyuhas, O., & Perry, R. P. (1992). The 5' TOP motif of ribosomal protein mRNAs is recognized by a specific trans-acting factor in quiescent cells. Gene Expression, 2(1), 93–101. https://pubmed.ncbi.nlm.nih.gov/1387319/

1. Avni, D., Shama, S., & Meyuhas, O. (1994). The 5' terminal oligopyrimidine tract of ribosomal protein mRNAs: a cis-acting regulatory element that confers translational repression in quiescent cells. Biochimie, 76(10–11), 1011–1015. https://doi.org/10.1016/0300-9084(94)90032-9

1. Meyuhas, O. (2000). Synthesis of the translational apparatus is regulated at the translational level. European Journal of Biochemistry, 267(21), 6321–6330. https://doi.org